According to Zacks, “Leap Therapeutics, Inc. is a biopharmaceutical company. It develops novel therapeutics for the treatment of cancer. Leap Therapeutics, Inc. is based in Cambridge, United States. “
LPTX opened at $1.47 on Friday. The company has a market capitalization of $33.74 million, a PE ratio of -0.59 and a beta of 2.23. Leap Therapeutics has a 12 month low of $1.35 and a 12 month high of $9.45.
Several institutional investors and hedge funds have recently bought and sold shares of the company. FMR LLC boosted its stake in Leap Therapeutics by 63.3% in the first quarter. FMR LLC now owns 1,563,124 shares of the company’s stock valued at $2,923,000 after acquiring an additional 606,000 shares in the last quarter. BlackRock Inc. boosted its stake in Leap Therapeutics by 57.3% in the first quarter. BlackRock Inc. now owns 24,451 shares of the company’s stock valued at $45,000 after acquiring an additional 8,906 shares in the last quarter. Deutsche Bank AG boosted its stake in Leap Therapeutics by 45.7% in the fourth quarter. Deutsche Bank AG now owns 124,338 shares of the company’s stock valued at $248,000 after acquiring an additional 39,000 shares in the last quarter. Virtu Financial LLC acquired a new position in Leap Therapeutics in the fourth quarter valued at $28,000. Finally, Vanguard Group Inc boosted its stake in Leap Therapeutics by 23.2% in the third quarter. Vanguard Group Inc now owns 256,268 shares of the company’s stock valued at $1,997,000 after acquiring an additional 48,300 shares in the last quarter. 8.26% of the stock is owned by institutional investors and hedge funds.
Leap Therapeutics Company Profile
Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer.
Read More: What is intrinsic value?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.